Fierce Health Payers January 28, 2020
Robert King

Editor’s note: A previous version of this story incorrectly identified who receives the drug discounts.

The federal government isn’t doing a good job of determining whether a drug company has to provide both 340B discounts and rebates for Medicaid, a federal watchdog said.

The Government Accountability Office (GAO) said in a report Tuesday (PDF) that the Centers for Medicare & Medicaid Services (CMS) only provides limited oversight of state efforts to quash duplicate discounts. Audits from the Health Resources and Services Administration (HRSA) are also lacking, the report found.

A safety net hospital can qualify to get a 25% to 50% discount for drug products under 340B, but those facilities are not eligible for drug rebates from Medicaid. A...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: GAO, Govt Agencies, Insurance, Market Research, Medicaid, Pharma, States, Trends
The Pharmacy Model Is Changing
Overturning Chevron Doctrine Could Impact Medicare’s Drug Selections For Price Negotiations
Merck Is Paying $588M for Potential Successor to Cancer Drug Juggernaut Keytruda
The financial burden of drug shortages: 7 study takeaways
What Stays True for U.S. Health Care Post #Election2024 (1) – Consumers’ Dissatisfaction with Drug Prices

Share This Article